Strive increased its Bitcoin holdings to 36,818 coins by purchasing 4,045 BTC between October 12 and 16 at an average price of around $82,000 per coin, spending about $100 million in the latest batch. This expansion of its corporate treasury comes ahead of a $630 million preferred stock offering, which is expected to settle on October 20. The proceeds from the stock sale will be used for general corporate purposes, including potential further Bitcoin purchases, working capital, and share buybacks. As of October 16, Strive held $317.5 million in cash and equivalents, signaling strong liquidity alongside its growing Bitcoin assets.
Strive's recent Bitcoin accumulation is context for readers following cryptocurrency markets. As of Oct 19, 2026 22:31 WIB, 41 of 50 major cryptocurrencies on Pluang rose while 8 fell. Notable movers include GRT at Rp433 with a 3.54% increase and a Pluang order activity of 90% Sell / 10% Buy, SNX at Rp3.868 up 3.17% with 52% Sell / 48% Buy, and XRP at Rp23.517 rising 3.09% with 49% Sell / 51% Buy. The most notable figure is GRT's 90% sell order activity on Pluang.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
